Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

222.11 +3.22 (+1.47%)
Delayed Quote Updated: 11:47 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings?
ResMed currently trades at $218.94 per share and has shown little upside over the past six months, posting a small loss of 2.7%. The stock also fell short of... 
Via StockStory
News headline image
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand ↗
ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing... 
Via MarketBeat
Discover which S&P500 stocks are making waves on Tuesday. ↗
Via Chartmill
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts ↗
Via Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume. ↗
Via Chartmill
ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9% ↗
Via Chartmill
ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health ↗
Via Chartmill
News headline image
Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including ResMed (NYSE:RMD) and its peers. Patient monit... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Profitable Stocks Worth Investigating and 1 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
2 S&P 500 Stocks with Promising Prospects and 1 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
ResMed (RMD) Q4 2026 Earnings Call Transcript ↗
Farrell discusses strategic divestitures, capital returns, and AI digital health expansion. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion ↗
Via Chartmill
News headline image
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management ... 
Via StockStory
Topics Earnings Economy
Which S&P500 stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
ResMed Q4 Earnings Call Highlights ↗
ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share... 
Via MarketBeat
Topics Earnings Economy
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
Top S&P500 movers in Friday's session ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
Which S&P500 stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP ... 
Via StockStory
Topics Economy
News headline image
ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP ... 
Via StockStory
News headline image
ResMed (RMD) Q2 Earnings: What To Expect
Medical device company ResMed (NYSE:RMD) will be announcing earnings results this Thursday after the bell. Here’s what to expect. ResMed beat analysts’ reven... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
3 Large-Cap Stocks to Consider Right Now
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
3 Cash-Heavy Stocks to Research Further
A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital. Not... 
Via StockStory
News headline image
2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
Top S&P500 movers in Monday's session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.